Home / Knowledge hub /
Navigating the transition to next-generation propellants for pMDIs | On-demand webinar
December 10, 2025
Regulators, health systems and patients expect meaningful progress on sustainability. For pressurized metered dose inhalers (pMDIs), this means planning the transition to low global warming potential (low-GWP) next-generation propellants (NGPs) now, not at the end of the decade.
In this webinar with Pharmaceutical Technology, Craig Somerville, Senior Vice President of Kindeva’s pMDI business unit, shares a practical view of what it takes to move existing products to NGPs while maintaining performance, supply continuity and patient need for MDIs.
Drawing on Kindeva’s pMDI pedigree built on inventing and industrializing the MDI, and its current investments in commercial-scale NGP capability, Craig outlines how a strategic drug delivery CDMO partner can help you move from feasibility to full-scale commercial supply with confidence.
Highlights include:
- The drivers accelerating the shift to NGPs
- What NGP-ready manufacturing and reformulation require
- Key considerations for HFA-152a and maintaining equivalent MDI performance
- How regulators are approaching the transition
- Where Kindeva adds value from feasibility through to commercial supply
Watch the webinar →
Access this content
Fields marked with a * are required.
Related resources
Explore our other resources to discover valuable insights on the latest trends in drug delivery.
Turning media fill data into stronger aseptic control in an Annex 1 era
Media fills provide an important demonstration of aseptic process performance, as the information gathered during a simulation gives manufacturers a stronger understanding of how the process behaves over time. As companies must now translate their media fill processes to meet Annex 1 expectations, the way this information is reviewed can provide valuable insight into aseptic […]
Learn More
Rethinking media fill strategy in the Annex 1 era
Media fills play a central role in aseptic process validation, providing a practical demonstration that a manufacturing process can be carried out without introducing microbial contamination. However, under the revised EU GMP Annex 1 guidance, the focus has shifted, and an acceptable final incubation result is no longer sufficient on its own. Now, media fills […]
Learn More
What’s behind the decisions shaping successful fill finish programs?
Advanced equipment and available cleanroom capacity are important considerations when choosing a sterile fill finish CDMO partner, but they only form part of the decision. As a drug program nears cGMP manufacturing, careful consideration of technical, quality, and operational readiness is essential, as it shapes how confidently a program can progress. These considerations take place […]
Learn More
Building sterile injectable manufacturing capacity for growing GLP-1 demand
Glucagon-like peptide-1 (GLP-1) receptor agonists are being prescribed more frequently, increasing pressure on sterile injectable manufacturing networks. To effectively serve expanding patient populations, developers must increase output while maintaining product quality and regulatory compliance without disrupting the supply of other therapies. Meeting the growing GLP-1 demand requires manufacturing models that can manage high-volume programs alongside […]
Learn More
Meeting the challenges of fill finish manufacturing
How flexible infrastructure and early manufacturing expertise can help drug developers respond to changing demand With rising demand for glucagon-like peptide-1 (GLP-1) medicines, continued progress in biologics and the expansion of self-administered treatments, new expectations are being placed on sterile fill finish operations. Manufacturers must accommodate different container formats and production volumes while maintaining consistent […]
Learn More
Can one quality system manage complexity across multiple drug delivery platforms?
As drug development portfolios expand across multiple delivery platforms, increasing complexity places quality systems under greater strain. For sponsors considering a CDMO, it is essential to know that the Quality Management System (QMS) can provide consistency while allowing teams to respond appropriately to the requirements of each product. A harmonized QMS can provide that framework […]
Learn More
Parenteral precision: Upstream formulation handling before sterile fill finish
Parenteral precision is a blog series exploring the controls, technologies and design decisions that shape modern parenteral manufacturing. Each article looks at one capability through a practical lens: what it is, how it works, who it supports and why it matters. In our first blog, we explored how sterile fill finish operations are designed around […]
Learn More
Delivering tomorrow’s injectables, today
Injectable therapies are entering a new phase of complexity. Biologics, personalized medicines and combination products are increasing demand for delivery systems that must adapt to more diverse formats and patient needs. Expectations around speed and compliance also continue to rise across the development lifecycle, placing greater pressure on how these systems are designed and scaled. […]
Learn More
Green propellants and the future of metered dose inhalers
The transition to next-generation propellants (NGPs) with low global warming potential (GWP) is redefining what success looks like for pressurized metered dose inhalers (MDIs). As sustainability targets tighten, developers must rethink how inhaled therapies are formulated, tested and manufactured without compromising performance. Reformulating with NGPs affects not only the drug product but also its interaction […]
Learn MoreLet’s transform tomorrow together
Every patient deserves a brighter tomorrow. As your strategic partner, we are dedicated to building your lasting legacy and helping you fast-track healthier tomorrows. You dream it, we deliver it.